Trial · NCT07103655
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage change in pressure gradient during the Valsalva maneuver | Week 36 | The percentage reduction in the pressure gradient at the site of left ventricular obstruction during the Valsalva maneuver at week 36, compared to baseline, as measured by echocardiography. |
| Secondary | Anterior papillary muscle to the interventricular septum distance | Week 36 | Percentage Increase in the distance from the anterior papillary muscle to the interventricular septum |
| Secondary | Left atrial global longitudinal strain | Week 36 | Left Atrial Global Longitudinal Strain (LA GLS) is an echocardiographic parameter derived from speckle-tracking imaging that measures the longitudinal deformation of the left atrial myocardium throughout the cardiac cycle. |
| Secondary | Left ventricular global longitudinal strain | Week 36 | Left Ventricular Global Longitudinal Strain (LVGLS) is a sensitive echocardiographic parameter derived from speckle-tracking imaging that quantifies the myocardial deformation in the longitudinal direction. It reflects the shortening of myocardial fibers along the long axis of the left ventricle during systole. |
| Secondary | Percentage change in resting pressure gradient | Week 36 | The percentage reduction in the pressure gradient at the site of left ventricular obstruction at rest measured by echocardiography at week 36 compared to baseline. |
| Secondary | Absolute change in pressure gradient during the Valsalva maneuver | Week 36 | The absolute decrease in number of the pressure gradient at the site of left ventricular obstruction during the Valsalva maneuver measured by echocardiography at week 36 compared to baseline. |
| Secondary | The proportion of patients with a pressure gradient <30 mmHg during the Valsalva maneuver | Week 36 | The proportion of patients with a pressure gradient \<30 mmHg at the site of obstruction during the Valsalva maneuver at week 36. |
| Secondary | BNP | Week 36 | Number decrease in BNP levels from baseline to week 36. |
| Secondary | Troponin T | Week 36 | Number decrease in Troponin T levels from baseline to week 36. |
| Secondary | New-onset atrial fibrillation | From baseline to week 36 | Rate of new-onset atrial fibrillation in each group during the study period |
| Secondary | LVEF<50% | From baseline to week 36 | The proportion of patients in each group with LVEF \<50% accompanied by signs and symptoms of heart failure worsening and/or an increase in BNP of ≥30% compared to the previous measurement during the study period. |
| Secondary | LVEF<40% | From baseline to week 36 | Rate of LVEF \<40% in each group during the study period. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07103655/registered